SAB Biotherapeutics is trading 6.27% higher at $2.96 on October 27, 2026; the specific cause of the move remains unclear. - October 27 coverage discusses trial progress and the antibody platform but does not identify a reason for the price action. - Broader markets are mixed: the Nasdaq is up 0.68% and the S&P 500 is up 0.26%. Available evidence does not establish that the stock’s gain is market-driven.